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 INTRODUCTION 
 The 8-aminoquinoline primaquine is a key antimalarial drug 
for both  Plasmodium falciparum and  P. vivax . Primaquine is a 
tissue schizontocide that kills early liver stages of  P. falciparum 
and  P. vivax , thereby providing causal prophylaxis against both 
infections. 1 Antischizontocidal activity can be achieved with a 
single dose of 30 mg primaquine within 48 hours of sporozo-
ite inoculation. Primaquine is also the only clinical agent that 
kills  P. vivax dormant stages (hypnozoites) and  P. falciparum 
stage 5 gametocytes. The World Health Organization (WHO) 
recommendations to eliminate  P. vivax hypnozoites and pre-
vent  P. vivax relapse are 0.25–0.50 mg/kg per day for 14 days 
(for persons with normal glucose 6 phosphate dehydrogenase 
[G6PD] levels). 2 The recommended regimen to kill  P. falci-
parum gametocytes and prevent transmission is one dose of 
0.75 mg/kg. 2 
 The antigametocyte and antirelapse indications are being 
increasingly emphasized. For  P. falciparum infection in 
Myanmar treated with standard blood schizontocidal regi-
mens, patients were randomized to one dose of primaquine 
(75 mg base/kg) or no treatment. 3 The incidence of gameto-
cytemia was 66 gametocyte-person-weeks per 1,000 weeks of 
follow-up in the non-primaquine group versus 5 gametocyte-
person-weeks in the primaquine group. In the same study, 
there were 69 patients who had recurrences of  P. falciparum 
infection, but 330 patients had recurrences of  P. vivax , includ-
ing 235 patients who, on the basis of light microscopy, appar-
ently presented only with  P. falciparum . A 2011 study on the 
Thai–Myanmar border confirmed that, because  P. vivax may 
be unrecognized in  P. falciparum infection, the “most com-
monly transmitted parasite after treatment for  falciparum 
malaria, paradoxically, was not  P. falciparum , but  P. vivax .” 4 
 The use of primaquine for any of these indications is lim-
ited, however, by its hemolytic toxicity in G6PD-deficient 
patients. At least 200 G6PD genetic variants are known 5 and 
are classified according to the phenotype. Classes I–IV are, 
respectively, completely enzyme deficient with chronic non-
spherocytic hemolytic anemia (class I), severely deficiency 
with < 10% of normal activity (class II), mildly/moderately 
deficient with 10% to 60% of normal activity (class III), and 
very mildly deficient or not deficient with 60% to 100% of 
normal activity (class IV). 6 G6PD deficiency is X-linked. The 
hemizygous male with the common African variant G6PD 
A- is typically mildly/moderately deficient with 10–60% of 
normal activity. 6 In contrast, the hemizygous male with G6PD 
Mediterranean variant would be severely affected with < 10% 
of normal activity. 6 WHO recommendations for primaquine 
dosing reflect the need to diminish or avoid the drug depend-
ing on the severity of G6PD deficiency. Although daily pri-
maquine is recommended for patients who are G6PD normal, 
weekly primaquine is recommended for patients with mild to 
moderate G6PD deficiency, and primaquine is contraindicated 
for persons with severe G6PD deficiency. 2 
 It is postulated that the efficacy and toxicity of 8-
aminoquinolines, such as primaquine, are ultimately related to 
the generation of reactive oxygen intermediates. 7 
 Primaquine and similar 8-aminoquinolines were devel-
oped in the 1940s to 1950s. The literature detailing this work 
suggests that the efficacy and toxicity of 8-aminoquinolines 
may be modified by coadministration of blood schizontici-
dal agents. Some of the agents that were used in these com-
binations are now known to affect enzymes that metabolize 
primaquine and other 8-aminoquinolines. We review this liter-
ature to suggest methods by which changing 8-aminoquinoline 
pharmacokinetic/pharmacodynamic properties might be 
attempted. The ultimate aim was to identify a partner drug 
that will increase the therapeutic index and thereby, mitigate 
the therapeutic constraints of hemolytic toxicity in G6PD-
deficient patients. 
 REVIEW OF THE LITERATURE 
 8-aminoquinolines evaluated in humans.  The first 8-
amino quino line s to be extensively clinically investigated were 
pamaquine and pentaquine. Primaquine was developed in the 
1940s 7 and is the only 8-aminoquinoline that has been in clinical 
use since that time except for quinocide in the former Soviet 
Union. 8 Tafenoquine can be mentioned as a prominent clinical 
agent in present development. 7 For patients without the threat 
of hemolytic anemia caused by G6PD deficiency, primaquine 
dosing is limited by gastrointestinal side effects. Primaquine 
replaced pamaquine and pentaquine because of primaquine’s 
superior therapeutic index with respect to radical cure versus 
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gastrointestinal adverse events. 9 The structures of pamaquine, 
pentaquine, and primaquine are shown in Figure 1 .
 Augmentation of antirelapse efficacy of 8-aminoquinolines 
by coadministration of blood-stage antimalarials.  Clinical 
experiments in the 1940s and 1950s investigated the efficacy of 
8-aminoquinolines alone and combined with blood schizontici-
dal drugs in preventing relapse ( Table 1 ). Study subjects were 
challenged with the Chesson strain of  P. vivax through the 
bites of infected mosquitoes. After the subject had been febrile 
and had parasitemia for a few days, drug was administered to 
eliminate blood-stage parasites. The patient was then observed 
for recurrence of parasites. The rationale of these experiments 
was as follows: if a curative dose of a blood schizonticidal drug 
had been administered, any recurrence of parasites constituted 
relapse from dormant hypnozoites in the liver. The investigators 
validated this approach by showing that blood stage-induced 
infections in human volunteers (thereby lacking liver stages) 
consistently and completely cleared their infections after 
standardized blood schizontocidal therapies without recur-
rences over long periods of follow-up or risk of reinfection. 
 Alving and others 10 treated patients with quinine alone, 
pentaquine alone, or the combination. In all cases, blood-
stage parasites disappeared within 6 days. Subsequent para-
site recurrence rates were 92% for quinine alone (data not 
shown), 60% for pentaquine alone, and 17% for the combina-
tion. The similarity of parasite clearance times and recurrence 
times between the groups led Alving and others 10 to assume 
that, if recurrence of parasites after quinine alone was because 
of relapse, recurrence of parasites in the pentaquine groups 
would also be because of relapse. In this case, administration 
of quinine with pentaquine reduced the relapse rate of pen-
taquine alone. 
 Experiments with a sequential design were performed for 
quinine and other 8-aminoquinolines. When quinine, which 
has a short half-life, was administered several days before 
or after an 8-aminoquinoline, the effect on liver stages was 
as if each drug had been separately administered. In a small 
experiment, all patients given pamaquine followed by qui-
nine relapsed, whereas some patients in whom pamaquine 
was administered concurrently with quinine did not relapse. 11 
When quinine was administered before primaquine, relapse 
was seen in 79% of patients, whereas only 5% relapsed when 
the two drugs were administered at the same time. 12 Another 
group of patients received the long half-life drug chloroquine 
(1 g) on the first day of primaquine therapy. This group also 
showed less relapse (26%) compared with the group in which 
primaquine was administered after quinine. 
 Modification of 8-aminoquinoline toxicity by coad-
ministration of a blood schizonticide.  The side effects of 
8-aminoquinoline are gastrointestinal reactions, methemoglo-
binemia, and in persons with G6PD deficiency, mild to severe 
intravascular hemolysis. 13 Because methemoglobin forma-
tion is easily studied and quantified, the occurrence of this 
side effect in patients treated with 8-aminoquinolines alone can 
be compared with methemolgobinemia in patients treated with 
8-aminoquinolines combined with blood schizonticides ( Table 1 ). 
 Table 1 
 Modification of 8-aminoquinoline efficacy and toxicity by coadministered drugs 
8-AQ Dose Coadministered drug Dose
Number 
subjects/patients
Number relapse (%) or 
percent MetHgb (mean) Ref.
Efficacy against  P. vivax relapse
 Pentaquine 60 mg per day × 14 D None NA 5 3 (60%)  10 
 Pentaquine 60 mg per day × 14 D Quinine 2 g per day × 14D 47 8 (17%)  10 
 Pamaquine 15 mg per day × 28 D Quinine 2 g per day × 8 D after 8AQ 5 5 (100%)  11 
 Pamaquine 15 mg per day × 28 D Quinine 2 g per day × 28 D with 8AQ 5 3 (60%)  11 
 Primaquine 15 mg per day × 14 D Quinine 2 g per day × 14 D before 8AQ 19 15 (79%)  12 
 Primaquine 15 mg per day × 14 D Quinine 2 g per day × 14 D with 8AQ 19 1 (5%)  12 
 Primaquine 15 mg per day × 14 D Chloroquine 1 g with first day of 8-AQ 19 5 (26%)  12 
Toxicity: MetHgb formation
 Pamaquine 30 mg per day × 5-7 D None NA 29 4.4  14 
 Pamaquine 30 mg per day × 5-7 D Quinacrine Not stated 6 12.2  14 
 Pentaquine 60 mg per day × 14 D None NA 10 4.5  15 
 Pentaquine 60 mg per day × 14 D Quinacrine 5 g over 14 days 5 12.5  15 
 Pentaquine 60 mg per day × 14 D Quinine 2 g per day × 14 D 82 4.3  15 
 Pamaquine 31.5 mg per day × 14 D None NA 12 4.4  16 
 Pamaquine 31.5 mg per day × 14 D Quinine 2 g per day × 14 D 27 4.5  16 
 Primaquine 15 mg per day × 14 D None NA 10 6.1  16 
 Primaquine 15 mg per day × 14 D Quinine 2 g per day × 14 D 33 6.1  16 
 Primaquine 22.5 mg per day × 14 D None NA 16 10.2  16 
 Primaquine 22.5 mg per day × 14 D Quinine 2 g per day × 14 D 41 6.8  16 
 Primaquine 30 mg per day × 14 D None NA 24 11.2  16 
 Primaquine 30 mg per day × 14 D Quinine 2 g per day × 14 D 8 8.4  16 
 Primaquine 60 mg per day × 14 D None NA 8 14.7  16 
 Primaquine 60 mg per day × 14 D Quinine 2 g per day × 14 D 4 8.8  16 
 Primaquine 120 mg per day × 14 D None NA 5 20.1  16 
 Primaquine 120 mg per day × 14 D Quinine 2 g per day × 14 D 6 9.9  16 
 Note that 8-aminoquinoline doses refer to milligrams of base. Quinine doses refer to grams of sulphate. Chloroquine dose refers to grams of base. Quinacrine dose refers to grams of the hydro-
chloride. 8-AQ = 8-aminoquinoline; D = day; MetHgb = methemoglobin; PQ = primaquine. 
 Figure 1.  Clinical 8-aminoquinolines . 
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 Quinacrine given with an 8-aminoquinoline increased the 
amount of methemoglobinemia compared with the amount 
that was seen when the 8-aminoquinoline alone was admin-
istered. In patients being treated with pamaquine alone or 
pamaquine plus quinacrine, the percent methemoglobinemia 
after 5–7 days of therapy was 4% for the pamaquine alone 
group versus 12% for the combination group. 14 When pen-
taquine was administered alone or with quinacrine, the per-
cent methemoglobin also increased from 4% to 12%. 15 
 In contrast, the combination of quinine and 8-aminoquinolines 
did not lead to an increase in percent methemoglobin. No change 
between the methemoglobin value for the 8-aminoquinoline 
alone versus the combination with quinine was seen for pen-
taquine 15 and pamaquine, 16 and for primaquine, combination 
with quinine led to an apparent decrease in methemoglobin 
in a dose-related fashion. 16 In the same work, chloroquine 
seemed to have a similar effect in malaria patients but not in 
normal volunteers. 
 We were able to find one study in which hemolysis rather 
than methemoglobin formation was the endpoint. Although 
this study used pentaquine at a high dose (120 mg/day for 
14 days), it is of interest that, in four patients given this dose 
alone, there was a mean loss of hemoglobin of 3.2%, whereas 
in four patients given this dose plus quinine, the loss of hemo-
globin was much diminished at 0.1%. 17 
 These results may be explained on a pharmacokinetic basis 
(see below). 
 Pharmacokinetics and metabolism of the 8-aminoquinolines. 
 Pamaquine and pentaquine.  Sparse information is available 
for these old drugs. After oral dosing of pamaquine in humans, 
peak serum levels are achieved at approximately 3 hours, and 
then, they decline with a half-life of approximately 2 hours. 18 
Zubrod and others 18 also commented that the “pathway of 
metabolism of the drug is not known. [There is e]vidence for 
the presence of two metabolic intermediates.” 18 These two 
metabolites were not identified but would likely represent 
products of cytochrome P450 or oxidative deamination 
pathways. Armer and others 19 found that the activity of 
pentaquine against coccidian parasites was inhibited by mono-
amine oxidase inhibitors but not cytochrome P450 inhib-
itors, 19 suggesting that one of the products of this pathway 
may mediate the drug’s antiparasitic effect. The importance 
of the monoamine oxidase metabolic pathway is becoming 
increasingly recognized for primaquine as well (see below). 
 Primaquine.  Absorption is linear over the doses of 15–
45 mg. 13 After a 45 mg dose, the time of maximum concentration 
is 3 hours and the maximum concentration is 153 ng/mL . 13 
The mean elimination half-life of primaquine was 4–7 hours 
in several studies. Primaquine itself is generally believed 
unlikely to be the clinically active form of the drug, because 
it is exten sively metabolized and less active than some of 
its metabolites or derivatives (for example, 4-hydroxy pri-
maquine and 5-hydroxy,6-demethyl primaquine) in  in vitro 
models. 20 
 The predominant contributors to primaquine metabolism by 
human liver microsomes were cytochrome P450 (CPY) 1A2, 
2B6, 2D6, and 2E1. 21 Elsewhere, primaquine is noted to inhibit 
CYPs 1A2, 2D6, and 3A4 and induce CYP 1A2. 22 In healthy 
volunteers, the maximum concentration of primaquine was 
increased by a mean of 23% and area under the curve (AUC) 
of 19% when administered with grapefruit juice, 23 suggesting 
inhibition of intestinal CYP450-mediated metabolism and/
or interaction with transport by P-glycoprotein and organic 
anion-transporting polypeptides. 24 
 There is a large body of evidence that primaquine is con-
verted by oxidative deamination to the carboxylic acid 
metabolite carboxyprimaquine, which is the predominate spe-
cies circulating in plasma after oral administration in man. 23 
Monoamine oxidase (MAO) in mitochondria converts pri-
maquine to primaquine aldehyde, which can then be con-
verted to primaquine alcohol or primaquine carboxylic acid 
(carboxyprimaquine). 25 Strong evidence for the pathway 
primaquine—primaquine aldehyde—carboxyprimaquine was 
seen in  in vitro cell models. 26 Recently, we showed MAO-A 
(but not MAO-B) isoenzyme-mediated metabolism of pri-
maquine with the concurrent appearance of masses consis-
tent with carboxyprimaquine formation (Pybus B and others, 
unpublished data). 
 It is evident that primaquine is a substrate for cyto chrome 
P450-mediated oxidation and also monoamine oxidase- 
mediated metabolism. Both efficacy and hemolysis seem to 
depend on metabolic activation of the parent drug, but firm 
evidence as to which metabolites mediate efficacy and toxicity 
is lacking at present. 
 Determination of metabolic pathways that lead to efficacy 
is difficult, because there is no  in vitro model of hypnozoites 
within liver cells with which to evaluate efficacy; however, 
evaluation of pathways that lead to toxicity in the sense of 
methemoglobin formation can be performed. Formation of 
methemoglobin by primaquine increased at least 10 times 
by coincubating red cells with human liver microsomes, and 
this metabolic conversion could also be accomplished by 
recombinant human CYPs 1A2, 3A4, 2D6, 2B6, and 2E1. 27 
Inhibitors of CYPs 2B6, 2D6, and 3A4 caused significant 
inhibition of the methemoglobin formation mediated by the 
microsomes. 
 Transport of 8-aminoquinolines into and out of liver cells 
seems not to have been investigated, but quinidine is a recog-
nized inhibitor of human P-glycoprotein and organic cation 
transporter 1 (quinine also inhibits this transporter) and is a sub-
strate for organic cation transporter 2. 28 Intrahepatic or intra-
parasitic 8-aminoquinoline levels might be modified by changes 
in 8-aminoquinoline transport by coadministered drugs. 
 Potential for drug–drug interaction by combination partners. 
 Quinine is metabolized largely by CYP 3A4. 21 Elsewhere, 
quinine is noted to be a substrate of CYPs 1A2 and 2C19 
and inhibit CYPs 2C8, 2C9, 2D6, and 3A4. 29 Chloroquine is 
reported to be metabolized by CYPs 2C8, 2D6, and 3A4 30 and 
inhibit CYP 2D6. 31 Quinacrine is metabolized by CYP 3A4 32 
and results in a significant decrease of CYP 2E1 activity and 
expression. 33 
 Alterations in pharmacokinetics/metabolism of the 8-
amin oquinolines by coadministered blood schizonticides. 
 Pamaquine exposure seems to be increased by the coadminis-
tration of quinacrine. 18 In four patients, pamaquine concen-
trations after coadministered drug were at least six times the 
level before quinacrine was administered, and the half-lives 
approximately quadrupled. Clayman and others 16 found a 
dose-related decrease in primaquine concentrations with 
coadministration with quinine from no apparent effect at 
22.5 mg to a 50% reduction at 120 mg primaquine. Edwards and 
others 34 showed that the conversion of primaquine to a major 
but inactive metabolite, carboxyprimaquine, was diminished 
in the presence of quinine. The AUC for carboxyprimaquine 
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when primaquine alone was administered was 7,533 μg/L-hour 
versus 3,831 μg/L-hour when primaquine plus quinine was 
administered. 34 However, the AUC of primaquine was 
unchanged, 34 suggesting a shift to a different metabolic 
pathway. 
 DISCUSSION 
 The antirelapse activity of pentaquine, pamaquine, and pri-
maquine in humans was increased by coadministration of qui-
nine, and the antirelapse activity of primaquine was increased 
by chloroquine. Methemoglobin formation because of pen-
taquine or primaquine was increased by the coadministra-
tion of quinacrine but importantly, not by quinine. The overall 
data suggest that efficacy and toxicity of 8-aminoquinolines 
are modifiable by drug coadministration. Importantly, the qui-
nine data suggest that efficacy and toxicity can be differen-
tially modifiable. The likelihood that these pharmacodynamic 
changes reflect altered 8-aminoquinoline metabolism is sup-
ported by the changes in pamaquine exposure by quinacrine 
and carboxyprimaquine exposure by quinine. 
 Although active metabolites of primaquine have not been 
identified,  in vitro studies indicate metabolism of the par-
ent compound by CYPs and monoamine oxidases, especially 
monoamine oxidase-A (Pybus B and others, unpublished 
data), and perhaps other amine oxidases as well (Walker  L 
unpublished data). The coadministered drugs quinine, chloro-
quine, and quinacrine are known substrates or inhibitors of a 
wide range of CYPs. Interaction of these coadministered drugs 
with amine oxidases and transporters has not been detailed. 
We hypothesize that alteration of primaquine pharmacody-
namics and pharmacokinetics by drug combinations is based 
on competition between the 8-aminoquinoline and coadmin-
istered drugs for CYPs, other metabolizing enzymes such as 
oxidases, and/or transporters. 
 We have used methemoglobin formation as a surrogate 
marker for red cell toxicity, because methemoglobin seems 
to be a consistent hallmark response to 8-aminoquinolines, 
and these data are readily available in many clinical studies. 
However, hemolysis in G6PD deficiency is the toxicity that 
is limiting clinical use, and data are not available on drug 
interactions and direct hemolytic risk. There seems to be a 
link between hemolysis and methemoglobin formation, both 
resulting from the oxidative stress elicited in erythrocytes. 
However, the direct mechanistic link is unclear. Most drugs 
that cause hemolysis in G6PD-deficient persons also generate 
methemoglobinemia, although nitrite causes methemoglobin-
emia but not hemolysis in this patient population. 35 
 The key reason that little is known about hemolytic toxicity in 
G6PD is the lack of preclinical models and the difficulty of con-
ducting clinical studies. The Nonhemolytic 8-Aminoquinoline 
Consortium is now qualifying preclinical G6PD mouse mod-
els to solve this problem. These models include two qualified 
mouse models: a G6PD mutant and a severe combined immu-
nodeficiency (SCID) mouse model in which G6PD-deficient 
human red cells are infused into the animal (unpublished 
data). A monkey model in which glutathione-depleted Rhesus 
red cells are infused back into the animal is also under devel-
opment. Human studies for evaluation of safety of primaquine 
and tafenoquine in G6PD patients are also ongoing and pav-
ing the way for assessing drug combinations in the clinic in the 
future. 
 Drug combinations will not be of clinical value if efficacy 
and toxicity are increased in tandem. The quinine data lead us 
to think that 8-aminoquinoline efficacy and toxicity are caused 
by different 8-aminoquinoline metabolites and that efficacy 
may be increased without increasing toxicity. To investigate 
this hypothesis, we intend to coadminister primaquine with 
quinine or chloroquine and with known clinical inducers and 
inhibitors of cytochromes, oxidases, and transporters in pre-
clinical efficacy and toxicity models. If we are correct, it may be 
possible to increase the therapeutic index of primaquine, and 
ultimately tafenoquine, with coadministration of other clinical 
agents, and thus may optimize the treatment of malaria with 
8-aminoquinolines. With the new models and human capabil-
ity now available, we hope to substantially impact malaria pre-
vention, control, and elimination. 
 Received August 1, 2011. Accepted for publication September 13, 
2011. 
 Acknowledgments:  This project was partially supported by Grant 
W81-XWH-07-2-0095 to the University of Mississippi (awarded 
and administered by the US Army Medical Research and Material 
Command [USAMRMC] and the Telemedicine and Advanced 
Technology Research Center [TATRC] at Fort Detrick, MD and the 
Department of Defense). The views, opinions, and/or findings con-
tained in this paper are the authors and do not necessarily reflect the 
views of the Department of Defense; they should not be construed as 
an official Department of Defense/Army position, policy, or decision 
unless so designated by other documentation. The American Society 
of Tropical Medicine and Hygiene (ASTMH) assisted with publica-
tion expenses 
 Authors’ addresses: Hla Y. Myint, Jonathan Berman, Brandon 
Pybus, Victor Melendez, and Colin Ohrt, Division of Experimental 
Therapeutics, Walter Reed Army Institute of Research, Silver Spring, 
MD, E-mails:  Hya.yin.myint@us.army.mil ,  Jbe9320457@aol.com.  bran
don.pybus@us.army.mil ,  Victor.melendezsr@us.army.mil , and  colin
.ohrt@us.army.mil . Jonathan Berman, North Bethesda, MD, E-mail: 
 Jbe9320457@aol.com . Larry Walker, Department of Pharmacology 
and National Center for Natural Products Research, School of 
Pharmacy, University of Mississippi, University, MS, E-mail:  lwalker@
olemiss.edu . J. Kevin Baird, Eijkman–Oxford Clinical Research Unit, 
Jalan Diponegoro No. 69, Jakarta, Indonesia, and Centre for Tropical 
Medicine, Nuffield Department of Clinical Medicine, University of 
Oxford, Oxford, United Kingdom, E-mail:  jkevinbaird@yahoo.com . 
 REFERENCES 
  1.  Baird  JK ,  Fryauff  DJ ,  Basri  H ,  Bangs  MJ ,  Subianto  B ,  Wiady  I , 
 Purnomo,  Leksana B ,  Masbar  S ,  Richie  TL ,  Jones  TR ,  Tjitra  E , 
 Wignall  ES ,  Hoffman  SL ,  1995 .  Primaquine for prophylaxis 
against malaria among nonimmune transmigrants in Irian Jaya, 
Indonesia .  Am J Trop Med Hyg  52:  479 – 484 . 
  2.  World Health Organization ,  2006 .  Guidelines for the Treatment 
of Malaria ,  2nd ed .  Geneva, Switzerland :  World Health 
Organization ,  52 – 58 . 
  3.  Smithuis  F ,  Kyaw  MK ,  Phe  O ,  Win  T ,  Aung  PP ,  Oo  AP ,  Naing  AL , 
 Nyo  MY ,  Myint  NZ ,  Imwong  M ,  Ashley  E ,  Lee  SJ ,  White  NJ , 
 2010 .  Effectiveness of five artemisinin combination regimens 
with or without primaquine in uncomplicated falciparum 
malaria: an open-label randomised trial .  Lancet Infect Dis  10: 
 673 – 681 . 
  4.  Douglas  NM ,  Nosten  F ,  Ashley  EA ,  Phaiphun  L ,  van Vugt  M , 
 Singhasivanon  P ,  White  NJ ,  Price  RN ,  2011 .  Plasmodium vivax 
recurrence following falciparum and mixed species malaria: 
risk factors and effect of antimalarial kinetics .  Clin Infect Dis 
 52:  612 – 620 . 
  5.  Beutler  E ,  Duparc  S ,  2007 .  Glucose-6-phosphate dehydrogenase 
deficiency and antimalarial drug development .  Am J Trop Med 
Hyg  77:  779 – 789 . 
  6.  WHO Working Group ,  1989 .  G6PD deficiency.  Bull World Health 
Organ  67:  601 – 611 . 
1014 MYINT AND OTHERS
  7.  Brueckner  RP ,  Ohrt  C ,  Baird  JK ,  Milhous  W ,  2001 .  8-
aminoquinolines .  Rosenthal  PJ , ed.  Antimalarial Chemotherapy: 
Mechanisms of Action, Resistance, and New Directions in Drug 
Discovery .  Totowa, NJ :  Humana Press Inc . 
  8.  Lysenko  AV ,  1960 .  Use of quinocide in treatment and prophylaxis 
of vivax malaria .  Bull World Health Organ  22:  641 – 662 . 
  9.  Alving  AS ,  1954 .  Clinical treatment of malaria .  Recent Adv Med 
Surg  2:  209 – 218 . 
 10.  Alving  AS ,  Craige  B ,  Jones  R ,  Whorton  CM ,  Pullman  TN , 
 Eichelberger  L ,  1948 .  Pentaquine (Sn-13,276), a therapeutic 
agent effective in reducing the relapse rate in vivax malaria . 
 J Clin Invest  27:  25 – 33 . 
 11.  Craige  B ,  Jones  R ,  Whorton  CM ,  Pullman  TN ,  Alving  AS , 
 Eichelberger  L ,  1947 .  Clinical standardization of pamaquine 
(plasmochin) in mosquito-induced vivax malaria, Chesson 
strain .  Am J Trop Med  27:  309 – 315 . 
 12.  Alving  AS ,  Arnold  J ,  Hockwald  RS ,  Clayman  CB ,  Dern  RJ ,  Beutler 
 E ,  Cl  Flanagan ,  1955 .  Potentiation of the curative action of pri-
maquine in vivax malaria by quinine and chloroquine .  J Lab 
Clin Med  46:  301 – 306 . 
 13.  Hill  DR ,  Baird  JK ,  Parise  ME ,  Lewis  LS ,  Ryan  ET ,  Magill  AJ , 
 2006 .  Primaquine: report from CDC expert meeting on malaria 
chemoprophylaxis I .  Am J Trop Med Hyg  75:  402 – 415 . 
 14.  Earle  DP ,  Bigelow  FS ,  Zubrod  CG ,  Kane  CA ,  1948 .  Studies on the 
chemotherapy of the human malarias. IX. Effect of pamaquine 
on the blood cells of man .  J Clin Invest  27:  121 – 129 . 
 15.  Atchley  JA ,  Yount  EH ,  1948 .  Reactions observed during treat-
ment with pentaquine, administered with quinacrine (atabrine) 
metachloridine (sn-11,437) and with sulfadiazine .  J Natl Malar 
Soc  7:  118 – 124 . 
 16.  Clayman  CB ,  Arnold  J ,  Hockwald  RS ,  Yount  EH ,  Edgcomb  JH , 
 Alving  A ,  1952 .  Toxicity of primaquine in caucasians .  J Am Med 
Assoc  149:  1563 – 1568 . 
 17.  Craige  B ,  Eichelberger  L ,  Jones  R ,  Alving  AS ,  Pullman  TN , 
 Whorton  CM ,  1948 .  The toxicity of large doses of pentaquine 
(sn-13,276), a new antimalarial drug .  J Clin Invest  27:  17 – 24 . 
 18.  Zubrod  CG ,  Kennedy  TJ ,  Shannon  J ,  1948 .  Studies on the chemo-
therapy of the human malarias; the physiological disposition of 
pamaquine .  J Clin Invest  27:  114 – 120 . 
 19.  Armer  RE ,  Barlow  JS ,  Dutton  CJ ,  Greenway  D ,  Greenwood 
 S ,  Lad  N ,  Thompson  AP ,  Thong  K ,  Tommasini I, 1998. 
8-aminoquinolines as anticoccidials—II .  Bioorg Med Chem 
Lett  8:  1487 – 1492 . 
 20.  Bates  MB ,  Meshnick  SR ,  Sigler  CI ,  Leland  P ,  Hollingdale  MR , 
 1990 .  In vitro effects of primaquine and primaquine metabo-
lites on exoerythrocytic stages of  Plasmodium berghei .  Am 
J Trop Med Hyg  42:  532 – 537 . 
 21.  Li  XQ ,  Anders Bjorkman  AE ,  Andersson  TB ,  Gustafsson  LL , 
 Collen  AE ,  Masimirembwa  M ,  2003 .  Identification of human 
cytochrome P450s that metabolise anti-parasitic drugs and pre-
dictions of  in vivo drug hepatic clearance from  in vitro data . 
Eur J Clin Pharmacol  59:  429 – 442 . 
 22.  Available at :  http://www.merckmanuals.com/professional/print/
lexicomp/primaquine.html . 
 23.  Cuong  BT ,  Binh  VQ ,  Dai  B ,  Duy  DN ,  Lovell  CM ,  Rieckmann  KM , 
 Edstein  MD ,  2006 .  Does gender, food or grapefruit juice alter 
the pharmacokinetics of primaquine in healthy subjects?  Br J 
Clin Pharmacol  61:  682 – 689 . 
 24.  Seden  K ,  Dickinson  L ,  Khoo  S ,  Back  D ,  2010 .  Grapefruit–drug 
interactions .  Drugs  70:  2373 – 2407 . 
 25.  Constantino  L ,  Paixão  P ,  Moreira  R ,  Portela  MJ ,  Do Rosario 
 VE ,  Iley  J ,  1999 .  Metabolism of primaquine by liver homo-
genate fractions. Evidence for monoamine oxidase and cyto-
chrome P450 involvement in the oxidative deamination of 
pri maquine to carboxyprimaquine .  Exp Toxicol Pathol  51: 
 299 – 303 . 
 26.  Frisher  H ,  Meillovitz  RL ,  Ahmad  T ,  Nora  MV ,  1991 .  The conver-
sion of primaquine to primaquine-aldehyde, primaquine-
alcohol, and carboxyprimaquine, a major plasma metabolite . 
 J Lab Clin Med  117:  468 – 476 . 
 27.  Ganesan  S ,  Tekwani  BL ,  Sahu  R ,  Tripathi  LM ,  Walker  LA , 
 2009 .  Cytochrome P450-dependent toxic effects of pri-
maquine on human erythrocytes .  Toxicol Appl Pharmacol  241: 
 14 – 22 . 
 28.  FDA ,  2006 .  Guidance for Industry Drug Interaction Studies—
Study Design, Data Analysis, and Implications for Dosing and 
Labeling .  Rockville, MD: FDA . 
 29.  Available at :  http://www.merckmanuals.com/professional/print/
lexicomp/quinine.html .  Accessed June 5,  2011 . 
 30.  Projean  D ,  Baune  B ,  Farinotti  R ,  Flinois  J ,  Beaune  P ,  Taburet  A , 
 Ducharme  J ,  2003 .  In vitro metabolism of chloroquine: identifi-
cation of Cyp2c8, Cyp3a4, and Cyp2d6 as the main isoforms 
catalyzing  N -desethylchloroquine formation .  Drug Metab 
Dispos  31:  748 – 754 . 
 31.  Available at :  http://www.merckmanuals.com/professional/print/
lexicomp/chloroquine.html .  Accessed June 5,  2011 . 
 32.  Huang  Y ,  Okochi  H ,  May  B ,  Legname  G ,  Prusiner  SB ,  Benet  LZ , 
 Guglielmo  BJ ,  Lin  ET ,  2006 .  Quinacrine is mainly metabolized 
to mono-desethyl quinacrine by CYP3A4/5 and its brain accu-
mulation is limited by p-glycoprotein .  Drug Metab Dispos  34: 
 1136 – 1144 . 
 33.  Karamanakos  PN ,  Trafalis  DT ,  Geromichalos  GD ,  Pappas  P , 
 Harkitis  P ,  Konstandi  M ,  Marselos  M ,  2009 .  Inhibition of rat 
hepatic CYP2E1 by quinacrine: molecular modeling investiga-
tion and effects on 4-(methyl nitrosamino)-1-(3-pyridyl)-1-
butanone (NNK)-induced mutagenicity .  Arch Toxicol  83: 
 571 – 580 . 
 34.  Edwards  G ,  Mcgrath  CS ,  Ward  SA ,  Supanaranond  W , 
 Pukrittayakamee  S ,  Davis  TME ,  White  NJ ,  1993 .  Interactions 
among primaquine, malaria infection and other antimalarials in 
Thai subjects .  Br J Clin Pharmacol  35:  193 – 198 . 
 35.  Brewer  GJ ,  Tarlow  AR ,  Kellermeyer  RW ,  Alving  AS ,  1962 .  The 
hemolytic effect of primaquine. XV. Role of methemoglobin . 
J Lab Clin Med  59:  905 – 916 . 
